HansBiomed Corporation (KOSDAQ:042520)
19,500
+440 (2.31%)
At close: Aug 20, 2026
HansBiomed Revenue
HansBiomed had revenue of 36.35B KRW in the quarter ending June 30, 2026, with 64.95% growth. This brings the company's revenue in the last twelve months to 124.81B, up 45.85% year-over-year. In the fiscal year ending September 30, 2025, HansBiomed had annual revenue of 89.78B with 10.65% growth.
Revenue (ttm)
124.81B
Revenue Growth
+45.85%
P/S Ratio
2.23
Revenue / Employee
417.43M
Employees
299
Market Cap
278.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 89.78B | 8.64B | 10.65% |
| Sep 30, 2024 | 81.14B | 3.11B | 3.98% |
| Sep 30, 2023 | 78.03B | 3.57B | 4.80% |
| Sep 30, 2022 | 74.46B | 15.36B | 25.99% |
| Sep 30, 2021 | 59.10B | -21.00B | -26.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NIBEC | 32.34B |
| Genome & Company | 24.02B |
| S.Biomedics | 16.48B |
| Bio Solution | 15.82B |
| Kangstem Biotech | 3.42B |
| Inventage Lab | 3.16B |
| IntoCell | 2.47B |
| curacle co.,ltd. | 1.06B |